SOURCE: ContraFect Corporation
YONKERS, NY--(Marketwired - Sep 2, 2014) - ContraFect Corporation (NASDAQ: CFRXU), a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, is pleased to announce that ContraFect has been selected to give an oral presentation at the 54th ICAAC conference (the meeting of the American Society for Microbiology -- "ICAAC, the premier conference on antimicrobial agents and infectious diseases, showcases the latest-breaking science and lectures from top researchers around the world" -- http://www.icaac.org/). This year's ICAAC conference will take place September 5-9, 2014 at the Walter E. Washington Convention Center in Washington, D.C.
ContraFect's scientists will present the most recent findings on CF-301, an anti-infective agent with a novel mechanism of action that demonstrates potent activity against all drug-resistant and drug-sensitive forms of Staphylococcus aureus ("Staph"). The Company's presentation, titled, "Efficacy of Single-Dose Lysin CF-301 in Combination with Vancomycin (VAN) or Daptomycin (DAP) in Experimental Endocarditis (IE) Due to Methicillin-Resistant Staphylococcus aureus (MRSA)," will be presented by Michael Wittekind, Ph.D., chief scientific officer of ContraFect, in an oral format on September 9, 2014 at 10:45 AM in Room 144 A.
"We are delighted to present our latest data on CF-301 to the infectious disease community at the 54th annual ICAAC conference," stated Julia P. Gregory, chief executive officer of ContraFect. "This study illustrates ContraFect's new alternative approach to treating the life-threatening infectious disease of Staph bacteremia, demonstrating the powerful combination of CF-301 and standard-of-care antibiotics in this well established model of infectious endocarditis," commented Dr. Wittekind.
CF-301 is a bacteriophage lysin, which is an enzyme that digests bacterial cell walls, killing bacteria immediately upon contact. CF-301 has specificity for Staphylococcus aureus (Staph), and Group A and Group B streptococci, and has displayed activity against all forms of Staph, including methicillin-resistant (MRSA) and vancomycin-resistant isolates (VISA/VRSA). The initial indication being pursued for CF-301 is Staph bacteremia, a blood stream infection that causes 30,000 deaths per year in the U.S. alone.
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.
About the ICAAC
ICAAC, the premier conference on antimicrobial agents and infectious diseases, showcases the latest-breaking science and lectures from top researchers from around the world. With over 60% of its attendees living outside of the United States, ICAAC provides a rare opportunity to bring together the field's foremost leaders to discuss the state of infection control and prevention on a global scale. Through oral and poster presentations, 10,000 physicians, clinical microbiologists, researchers, and pharmacists will come together to share their research, discover the latest breakthroughs, and work towards fostering global solutions to the problems of infectious diseases and antimicrobial agents.
This press release includes forward-looking statements within the meaning of the U.S. federal securities laws. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to ContraFect's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of ContraFect's management but are subject to significant risks and uncertainties, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the timing for the separation of ContraFect's publicly traded units into their component securities as described herein) may differ from those set forth in the forward-looking statements. Except as required by applicable law, ContraFect expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in ContraFect's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.